(E) | 1. |
¦b¤ß¹q¹Ï§e²{¡G¤ß¶b¥ª°¾-45«×¡AqR ¦bI¤ÎaVLµ¥ÅܤƬO©Ò¿×"¥ª«e§ôªK¶Ç¾Éªýº¢" (Left anterior fascicular block)¡A½Ð°Ý¤U¦C¦óºØ»¡ªk¤£¥¿½T¡H
|
A. | ¥ª«e§ôªK²Óªø¡A¬ï¦æ¥ª¤ß«Ç¥X¤f³q¹D¦a±a¡A©ö¨ü¤ßÁYÀ£¤O¶Ë®`¡A¬O¥HÁ{§É¦h¨£¡C |
B. | ¥ª«e°¤ä«a¯ß(Left anterior descending artery)¨Ñ¦å¥ª«e§ôªK¡A¤£Y¥ª«á§ôªK¨Ñ¦å¨Ó¦Û¥ª¥kÂù±ø«a¯ß¡A¬O¥H©ö¦]¤ß¦Ù¯Ê¦å¶ËÅÜ¡Aµo¥Í¶Ç¾Éªýº¢¡C |
C. | «æ©Ê«e¾À¤ß¦Ù±ð¶ë¦pY¦ñµo¥k§ôªK¶Ç¾Éªýº¢(RBBB)¤Î¥ª«e§ôªK¶Ç¾Éªýº¢¡A©öP§¹¥þ¶Ç¾Éªýº¢(Complete heart block)¡C |
D. | ©Ò¿×"Âù§ôªK¶Ç¾Éªýº¢"ªx«üRBBB + Left anterior fascicular block¡BRBBB+ Left posterior fascicular block©ÎLBBB¡C |
E. | ¥ª«e§ôªK¶Ç¾Éªýº¢Y¦ñµo²Ä¤@«×©Ð«Ç¶Ç¾Éªýº¢(First degree A-V block)¡A ¤]©öP§¹¥þ¶Ç¾Éªýº¢(Complete heart block)¡C |
|
(B) | 2. |
¯f¤H²{¦~63·³®a®x¥D°ü¡A¦]¦³¯Ý´e¤Î®ð«P¨DÂå¡A¤»¦~«e´¿¦³°sºë©Ê¨xµw¤Æ¡A¨xŦ²¾´Ó¡C¤¦~«e¦]·P¬V©Ê¤ß¤º½¤ª¢¥HP¬I¦æ¹¬´Uä¸m´«(Hancock 27)¡A«ùÄòªù¶E°lÂܤ¤¡C¦åÀ£148/109 mmHg¡F¤ß¸õ152/min¡F©I§l¨C¤À27¦¸¡FÅé·Å37.5«×¡C¨ä¥L¨ÅéÀˬd¨ÃµL«¤j²§±`¡C¨ä¤ß¹q¹Ï(A.ªvÀø«e¡FB.ªvÀø«á)¦p¦C¡CÀˬd½T©w¤ßŦ§Ö¸õ¡A¦³¤U¦C¼Æ¶µ³B¸m±¹¬I¡G
1.ºò«æª`®gAdenosine ª`®g¾¯¶q150 mg IV¡C
2.ÀR¯ßª`¿é amiodarone 150 mg¡C
3.Rapid atrial pacing¡C
4.ºò«æSynchronized cardioversion 50-100 J¡C
5.ºò«æ·Ó·|¤ßŦ¬ì¬I¦æ¹p®g¿N¨`¤â³N (Radio-frequency catheter ablation)¡C
¨Ì¾Ú2015 ACC/AHA/HRS guideline¡A½Ð°Ý¦³Ãö¥»¯f¨Ò§Ö¸õ¤§³B¸m¡A¦ó¶µ³Ì²Å¦X" Class of recommendation I¡ª?
|
A. | 1+2+3 |
B. | 1+2+4 |
C. | 1+3+5 |
D. | 2+3+5 |
E. | 3+4+5 |
|
(D) | 3. |
¤ß©ÐÅÖºûŸ°Ê(Atrial fibrillation)¨Ï¥Î§Ü¦å®êªvÀø¡A¦bÁ{§É¤W¦³³\¦h¬ÛÃöªº±Ôz¡A½Ð°Ý¤U¦C¦óªÌ»¡ªk¬O¿ù»~ªº¡H
|
A. | Atrial fibrillation (Af)¦h¨£½Ñ¦Ñ¤H¡A80·³¥H¤H¬ù¦³10%¡C |
B. | ¤ßŦ¯f¤H¦pY¦ñ¦³Af¡A³£Äݯfª¬ÄY«¡C |
C. | ¦³Af¯f¤H¡A¸£¤¤·¦h¼W¤¿¡C |
D. | ¹êÃÒÂå¾Ç»{©wAspirin¥Î©óªvÀø¨S¦³¯gª¬ªºAf¡A¤]¥i¹w¨¾¦å®ê¶ë¡C |
E. | ¦Ñ¦~¡B°ª¦åÀ£¡B¿}§¿¯f¡B¤ßŦ¯f¤Î©I§l¤¤¤î¯g³£¬OAfªº¦MÀI¦]¯À¡C |
|
(C) | 4. |
¦³Ãö¤ßŦ°IºÜ (Heart failure) ªº±Ôz¡A¤U¦C¦ó¶µ¤£¥¿½T¡H
|
A. | ¤£ºÞ¤ßÁY©Î¤ßµÎ©Ê¤ßŦ°IºÜ¡A¦³ªñ¥b¯f¤H¤´Â¦³¥¿±`¥ª¤ß«Ç®g¥X²v(Left ventricular ejection fraction,LVEF)¡A¬O¥H±N¤ßŦ°IºÜ¤À¦¨1).HF reduced EF(HFrEF)¤Î2).HF preserved EF(HFpEF)¨âºØ¡C |
B. | ´N±±¨î¤ßŦ°IºÜ¤§§Ö¸õ(Tachycardia)¡AIvabradine»·¤ñDigoxin¬°¨Î¡C |
C. | ¹x©T©Ê¤ßŦ°IºÜÀ³¦P®É¨Ö¥ÎCaptopril + Valsartan + Carvedilol + Spironolactone¡C |
D. | «æ©Ê¥¢½Õ©Ê¤ßŦ°IºÜ(Acute decompensated heart failure¡AADHF)¦³30%¨Öµo¤ßµÇ¯gÔ¸s(Cardio-renal syndrome)¡A¨Ï¥Î§Q§¿¶q¼W¥[¦¹Ãþ¯f¤H¤§¤ßŦ±Æ¦å¶q(Cardiac output) ªvÀø¡A¤£ºÉ¦³®Ä¡C |
E. | ¨Ö¥ÎACEI¤ÎBeta-blocker¤£ºÉ¦³¯q©ó««×ADHF¤§ªvÀø¡C |
|
(B) | 5. |
¦³Ãö¯f¬r©Ê¤ß¦Ùª¢(Viral myocarditis) ±Ô»¡¡A¦bÁ{§É¤W®É¦³ªº°Oz¡A½Ð°Ý¤U¦C¦óºØ»¡ªk¬O¥¿½Tªº¡H
|
A. | ¯f¬r©Ê¤ß¦Ùª¢¦hµo¥Í¦b¦Ñ®z¯f¤H¡A¦hºØ¯e¯fÄñ¨¡C |
B. | ¦ñµo««×©I§l°IºÜ¤Î¤ß¦]©Ê¥ð§Jªº²r¼É©Ê¤ß¦Ùª¢(Fulminant myocarditis)¡A±`·|¨Öµo¦h¾¹©x°IºÜ¡C¦ý¤Î®Éªº¶EÂ_¤ÎªvÀø¥i±Ï©R¹L¥b¥H¤W¡C |
C. | ¤ß¦Ù¬¡Åé¤Á¤ùÀˬd(Endomyocardial biopsy)½T©w¶EÂ_²v°ª¡C |
D. | ¨´¤µ¬°¤îªº¹êÃÒÂå¾Ç³£»{©w§Ü¯f¬rÃĤΧK¬ÌÀ£¨îÀøªk(Immunosuppressive therapy)¬O¦³®ÄªºÀøªk¡C |
E. | ų©ó¤ß¦Ù¯f¬r½T©w¤£©ö¡A¥un¨Ö¦³¦Ù¦×»Äµh¤Î©I§l¯gª¬ªº·P¬V¡A¦P®É¦³¤ß¦Ù·l¶ËªºÀË©w¡A´N¥i½T¶E(Definite diagnosis)¤ß¦Ùª¢¡C |
|
(A) | 6. |
½Ð°Ý¦³Ãö«æ©Ê¤ß¦Ù±ð¶ë(Acute Myocardial Infarction) ªºÁ{§É»¡ªk¡A¥H¤U¦óªÌ¤£¥¿½T¡H
|
A. | ¨M©w«æ©Ê¤ß¦Ù±ð¶ëªº¤ß¹q¹ÏQªi¦b¯f²z¾Ç¥²©w¬O¥þ¾À©Ê¤ß¦Ù¯fÅÜ(Transmural infarction)¡C |
B. | «æ©Ê¤ß¦Ù±ð¶ë¯f¤H¤£©y¨Ï¥Îµu®ÄªºDihydropyridine¡A¦]¦h¼W¦º¤`²v¡C |
C. | NSTEMIªº«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¡A¤£©y¨Ï¥Î¦å®ê·»¸Ñ¾¯ªvÀø(Fibrinolytic therapy)¡C |
D. | Ãþ©T¾J(Glucocorticoid )¤ÎNSAID(Non-steroidal anti-inflammatory agents)³£¤£¦X¾A¦bSTEMI«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¨Ï¥Î¡C |
E. | Coronary care ªºÃĪ«¥]¬AStatin, Angiotensin receptor blockade, Beta-blockade¡A°£«D¦³¸T§Ò¡C |
|
(A) | 7. |
¯f¤H62·³¨k©Ê°Ó¤H¡A7:30AM¦¶º«á¯Ý¯k¨Ö¦³§N¦½¡A©ó8:11AM¨ì«æ¶E¨DÂå¡C¯f¤H¦³©â·Ï¤G¤Q¦~¤Î°ª¯×¦å²§±`ªº¯f¥v¡C¨ÅéÀˬd¡G¦åÀ£138/74 mmHg,¤ß¸õ96/¤À¡A³W«h¡A¤ßŦ·L¤j¡AS1¼x®z¡A¨S¦³S3©Î¤ßŦÂøµ¡A¨ä¥L©Ò¨£¥çµL«¤j²§±`¡C¨ä¤ß¹q¹Ï¦p¹Ï¡A¥Í¤ÆÀˬd¦b8:39AM¡GCK,204U/L¡FCK-MB,12U/L¡FTnI,<0.012ng/mL¡C
½Ð¤U¦C¦ó¶µ³B¸m³Ì¤£²Å¦X·í¤µ«ü¤Þ?
|
A. | ¤ß¹q¹Ï¤Î¤ß¦ÙúC³£¥¿±`¡A¯dÆ[§Y¥i¡C |
B. | ¨Ï¥ÎMorphine 3 mg IV¡C |
C. | ¥ýªA¥ÎTicagrelor 180 mg ¨Ö 90 mg BID + Chewable Aspirin 300mg loading and then 100 mg QD¡C |
D. | IV Heparin 5000 u bolus and then 600-1000 u/hour, depending on aPTT¡C |
E. | Atorvastatin 20 mg BID¡C |
|
(D) | 8. |
¯f¤H64·³¤k©Ê¡A¦b4¤ë11¤é²M±á«æ©Ê¯Ýµhµo§@¡A4AM°e¹FÂå°|¡A¯f¤H¦³°ª¦åÀ£¤Î¿}§¿¯f¦h¦~¡AÃĪ«ªvÀø¤¤¡C¨ÅéÀˬd¡G¦åÀ£216/114 mmHg¡F¤ß¸õ88/¤À¡A³W«h¡A¦b¥D°Êä°Ï¦³¤G«×¤ßÁYÂøµ¡A¾l©|µL«¤j²§±`¡C¥Í¤ÆÀˬd¡GCK 832 U/L, CK-MB 41 U/L, TnI 5.32 ng/mL(¤ß¹q¹Ï¦p¹Ï¥Ü)¡C«æ¶EÂå®vÀH§Y¦æDAPT loading¤ÎHeparination¡A¨Ã±Ò°ÊPCI¹Î¶¤¶i¦æ«a¯ß¦åºÞ¶EÂ_¤ÎªvÀø¡C½Ð°Ý¥»¯f¨Ò¤§Culprit lesion ³Ì¥i¯à¦b¦ó³B¡H
|
A. | Proximal left anterior descending artery |
B. | Proximal left circumflex artery |
C. | Distal left circumflex artery |
D. | Proximal right coronary artery |
E. | Distal right coronary artery |
|
(A) | 9. |
¯f¤H22·³¤k©Ê¥~Äy¬ÝÅ@¦]¦³¼Æ¤Ñªº¶¡·²©Ê¤ß±ª¤Î¯t·w¡A¶±¥D«æ°e«æ¶E³¡¨DÂå¡C¨ä¨ÅéÀˬd¡G«æ¯fÄp¡A¦åÀ£¡A88/72mmHg¡F¯ß¸õ¡A144/¤À¡A¤£³W«h¡F©I§l¡A28/¤À¡FªÍ³¡µL¿Bµ¡F¤ßŦ¡A¦³RV heaving¡AWide-splitting of S2¥i»D¡F«ü¦yµoÖæ¡F¾l§¡¥¿±`©Ò¨£¡C¤ß¹q¹Ï¦p¹Ï¥Ü¡C½Ð°Ý¨Ì¾Ú³Ì·sACC/AHA/HRS¤§Guideline¡A¦¹§Ö¸õ¦b«æ¶E³B¸m¡AÀ³¥H¦óºØ³B¸m³Ì«ê·í¡H
|
A. | Electric cardioversion 200 J after sedation |
B. | Adenosine 300 mg IV |
C. | Verapamil 5 mg IV |
D. | Amiodarone 150 mg in 10 min IV |
E. | Digoxin 0.25 mg in 5%D/W 20 ml for 5 min |
|
(D) | 10. |
¨Ì¾Ú2015 Guideline of Taiwan Society of Cardiology and Taiwan Hypertension Society for the Management of Hypertension¡A½Ð°Ý¤U¦C¦ó¶µ¤£¬OTaiwan Guidelineªº¥D±i¡H
|
A. | ¶uÆQ¦b2.0 gm/day¥H¤U¡C |
B. | ¨Ö¦³°ª¦åÀ£¤Î¿}§¿¯f¯f¤H¤§¦åÀ£¡AÀ³±±¨î¦b130/80 mmHg¥H¤U¡C |
C. | °ªÄ֦ѤH(>80·³)ªº¦åÀ£±±¨î¥Ø¼Ð±o¤É¦Ü150/90 mmHg¡C |
D. | ¦³³J¥Õ§¿ªººC©ÊµÇ¯f¤H©yºû«ù¦åÀ£¦b140/90 mmHg ¥H¤W¡A¥H¼W±jµÇ¤p²y¹LÂo²v(Glomerular filtration rate)¡C |
E. | ¨Ï¥Î§Ü¦å®êªvÀøªº¸£¤¤·¯f¤H¡AÀ³±±¨î¦åÀ£¦b130/80 mmHg ¥H¤U¡A¥H§K¸£¥X¦å¡C |
|
(B) | 11. |
58·³¨k©Ê«æ©Êµo§@°Ê³Ý»PºÝ§¤©I§l¨Ó«æ¶E¡A¯gª¬¤w¦³¤T¤Ñ¡A¨ÅéÀˬd¦b¤ß¦y³¡¦ì§e²{²Ä¤T¯Å¦¬ÁY´ÁÂøµ,¨Ã¿ç®g¦Ü¥ª«áI.¯Ý³¡X¥ú¤ù§e²{ªÍ¤ô¸~¡F¤ßŦ¶Wµªi§e²{¤G¦yäÂإͪ«(vegetation)¡A ¤G¦yä¸x¯ÁÂ_µõ»P««×¤G¦y䳬Âꤣ¥þ¡A¦å¤¤²Óµß°ö¾i3®M§e²{Streptococcus bovis. ½Ð°Ý°£¤F¤ß¤º½¤ª¢¥~¡A¤U¦C¯e¯f¦óªÌÀ³¦C¤J¶EÂ_¦Ò¶q?
|
A. | ªÍÀù |
B. | ¤j¸zÀù |
C. | ¥Òª¬¸¢Àù |
D. | »ó«|Àù |
E. | ¨ÅÀù |
|
(C) | 12. |
¦³Ãö24¤p®É¦åÀ£¶q´úªº´yz¦óªÌ¿ù»~?
|
A. | ©]¶¡¦åÀ£³q±`¤ñ¤é¶¡¦åÀ£§C10-20% |
B. | ¥Î24¤p®É¦åÀ£¶q´ú¶EÂ_°ª¦åÀ£®É,¥§¡²M¿ô¦åÀ£ (awake average blood pressure)¬O¥H¤j©óµ¥©ó135/85 ²@¦Ì¨E¬W¬°¶EÂ_°ª¦åÀ£¼Ð·Ç |
C. | ¥Î24¤p®É¦åÀ£¶q´ú¶EÂ_°ª¦åÀ£®É,¥§¡ºÎ¯v¦åÀ£(asleep blood pressure) ¬O¥H¤j©óµ¥©ó130/80²@¦Ì¨E¬W¬°¶EÂ_°ª¦åÀ£¼Ð·Ç |
D. | 24¤p®É¦åÀ£¶q´ú´£¨Ñ§ó¦hªº¤é¶¡»P©]¶¡¦åÀ£¼ÆÈ,¤ñ¶E¶¡¦åÀ£(office blood pressure)§ó¯à¥i¾a¹w´ú¾¹©x¶Ë®`( target organ damage). |
E. | ·í©]¶¡¦åÀ£°´T(dip)´î¤Ö®É,¤ß¦åºÞ¯e¯f·ÀI¤É°ª. |
|
(B) | 13. |
¤A«¬¨üÅéªýÂ_¾¯(beta-blocker)¥i¥Î©ó¥ª¤ß«Ç®g¥X¤À²v´î¤Ö®É¤§¤ßŦ°IºÜÃĪ«ªvÀø,¤U¦C±Ôz¦óªÌ¥¿½T?
1. ¥i¥H¨Ï¥Îxamoterol
2. ¥i¥H¨Ï¥Îbisoprolol
3. ¥i¥H¨Ï¥Îcarvedilol
4. ¥i¥H¨Ï¥Îpropranolol
5. ·í¯f¤H¨S¦³¥X²{§C¦åÀ£¾ÉPÀY·w©Î«å®É,¨C¹j¤@¶g¥i¥H©¹¤W½Õ¾ã¾¯¶q
|
A. | 1+5 |
B. | 2+3 |
C. | 2+3+5 |
D. | 2+4 |
E. | 3+5 |
|
(C) | 14. |
ìµo©ÊîÇ©T଼W¦h¯g (primary aldosteronism)±`³y¦¨°ª¦åÀ£,¦³Ãö¨ä¶EÂ_´yz,¦óªÌ¥¿½T?
1. ¦b«Dª×§É(ambulatory)ªº¯f¤H,²M±á©â¦å®É; ¦å²M¤¤îÇ©Tà¬/µÇ¯À¬¡©Ê(plasma aldosterone/ plasma renin activity) >30:1
2. ¦b«Dª×§Éªº¯f¤H,²M±á©â¦å;¦å²M¤¤îÇ©Tà¬>555pmol/L (>20ng/dL)
3. ¦b¦³°ª¦åÀ£¦Ó¥¼¨Ï¥Î§Q§¿¾¯¯f±w,¦å²M¤¤¹[Â÷¤l°§CªÌ,¦³°ª¹F90%¦³ìµo©ÊîÇ©T଼W¦h¯g
4. ¦b©â¦å«e4~6¶gn°±±¼îÇ©Tଫú§Ü¾¯(aldosterone antagonists)
5. ¦b¦å²MîÇ©Tà¬/µÇ¯À¤ñȤɰª±wªÌ,µ¹¤©ÀR¯ßª`®g2¤½¤É¥Í²z¹ÆQ¤ô¥|¤p®É«á,¦å²M¤¤ªºîÇ©Tର¦Ü138pmol/L (5ng/dL)¥H¤U
|
A. | 2+3+4 |
B. | 1+2+3 |
C. | 1+2+4 |
D. | 1+2+5 |
E. | 1+4+5 |
|
(C) | 15. |
¤@¦ì70·³¨k©Ê¯f±w¦]¤ß©ÐŸ°Ê´N¶E,¸Ó¤ß«ß¤£¾ã¯f¥v¤w¦³1¦~¥H¤W.¹L¥h¦³°ª¦åÀ£¤Î¿}§¿¯f¥v,³Ìªñ¦³°}µo©Ê©]¶¡©I§l§xÃø»P¸}³¡¤ô¸~;¤ßŦ¶Wµªi¥ª¤ß®g¥X¤À²v¬°29%.µL¤ß¦Ù±ð¶ë,¤¤·©Î¶gÃä¦åºÞªý¶ë¯e¯f¯f¥v.¦b¨M©wn¨Ï¥Î¤fªA§Ü¾®¦å¾¯®É;·|¦ôºâCHA2DS2-VASc ¤À¼Æ,½Ð°Ý¸Ó¯f±w¤§¤À¼Æ¬°?
|
A. | 2 |
B. | 3 |
C. | 4 |
D. | 5 |
E. | 6 |
|
(E) | 16. |
¤@¦ì25·³¨k©Ê¯f±w,¦]©ü³Ö¦Ó°e¦Ü«æ¶E.¦b«æ¶E¤§¤ß¹q¹Ï¦p¹ÏA. ¦^ÅU¸Ó¯f±w¥ý«eªù¶E12¾Éµ{¤ß¹q¹Ïªº²Ä¤@¦Ü²Ä¤T¯Ý«e¾É¦p¹ÏB.¸Ó¯f±w¤§¤ßŦ¶WµªiµLµ²ºc©Ê¤ßŦ¯f;¦å²M¹q¸Ñ½èµL²§±`,½Ð°Ý¤U¦C±Ôz¦óªÌ¬°»~?
|
A. | µ¹¤©¸Ó¯f±wflecainide·|Åý²Ä¤@¦Ü²Ä¤T¯Ý«e¾Éµ{ST¸`¬qÅܤƧó©úÅã |
B. | ¦³³¡¤À¯f¤H¦³¶uÂ÷¤l³q¹D(sodium channel)¬ðÅܲ§±` |
C. | ¯f¤H±`¦]µo¿N©ÎºÎ¯v»¤µo¤ß·i°±¤î(cardiac arrest) |
D. | ³oÃþ¯f¤H¦³®É»Ýn¸Ë¸m¤ß¤º¥hŸ¾ã¬y¾¹(ICD) |
E. | ¹[Â÷¤l³q¹D( potassium channel)²§±`¬Oµ´¤j³¡¤Àªºì¦] |
|
(E) | 17. |
¦³Ãö¤G¦y佤¯U¯¶ªºÂøµÅ¥¶E´yz,¦óªÌ¿ù»~?
1.·í¤G¦y佤¯U¯¶¶VÄY«,²Ä¤G¤ßµA2»P¤G¦yä¶}äµ(opening snap)ªº¶¡¶Z·|ÁYµu
2.·í¤G¦y佤±¿n¶V¨Ó¶V¯U¯¶,·|¤Þ°_¦¸µo©ÊªÍ°Ê¯ß°ªÀ£,¦¹®É²Ä¤G¤ßµP2·|ÅܤjÁn
3.·í¤G¦y佤±¿n¶V¨Ó¶V¯U¯¶,·|¤Þ°_¦¸µo©ÊªÍ°Ê¯ß°ªÀ£,¦¹®ÉA2»PP2¶¡¶Z·|Åܼe
4.¤G¦y佤¯U¯¶¬OµÎ±i´ÁÂøµ(diastolic rumble)
5.Austin-Flint murmur ¬O¥Î¨Ó´yz¤G¦yä¯U¯¶ªºÂøµ
|
A. | 1+3+5 |
B. | 1+4
|
C. | 2+3 |
D. | 3+4 |
E. | 3+5 |
|
(D) | 18. |
¦³Ãö¤G¸¦¡¥D°Ê¯ßä(bicuspid aortic valve)ªº´yz¦óªÌ¿ù»~?
|
A. | ¤G¸¦¡¥D°Ê¯ß䪺±wªÌ,¨ä¤@µ¥¿Ë¿©±w¸Ó¯e¯fªº²±¦æ²v(prevalence)¬°10% |
B. | ¤G¸¦¡¥D°Ê¯ß䪺±wªÌ¥D°Ê¯ß·|ÂX¤j,¦³®ÉÔ·|§Î¦¨¥D°Ê¯ß½F©Î¥D°Ê¯ßéÂ÷ |
C. | ¤G¸¦¡¥D°Ê¯ßä±wªÌªº¥D°Ê¯ß¯fÅÜ»P¥D°Ê¯ßä¯U¯¶¦å«¬¤O¾ÇªºÄY«µ{«×¤£¤@©w¦³¬ÛÃö( independent of the severity of hemodynamic severity of the valve lesions) |
D. | ¤G¸¦¡¥D°Ê¯ß䪺¨k¤k¤ñ¬°1:2~4 |
E. | ¤G¸¦¡¥D°Ê¯ßä·|»P¨ä¥L¥ý¤Ñ©Ê¤ßŦ¯f¦X¨Öµo¥Í |
|
(B) | 19. |
¤@¦ì82·³¨k©Ê¯f±w¦]°©ÀYÀ£µh¡A³Ý»P¸}¸~¦Üªù¶E´N¶E¡A¦åÀ£¬°96/60²@¦Ì¨E¬W¡A¤ß¸õ¨C¤ÀÄÁ¬°80¦¸¡A¨ÅéÀˬd§e²{¡Gµ²½¤»a¥Õ¡AÀVÀR¯ß«ã±i¡A¨â°¼©I§lµ´î®z¡A¤ßŦť¶E¥ª¤U¯Ý°©§e²{²Ä¤T¯Å¦¬ÁY´ÁÂøµ¡A¨ÃÀH§l®ð¥[«¡A¤ß¦y³¡§e²{²Ä¤T¯Å¦¬ÁY´ÁÂøµ¡A¨â°¼¤UªÏ©úÅã¤ô¸~¡C©â¦åÀˬd§e²{BUN 70 mg/dl, cre 5.5mg/dl, Na 140 mmol/L, K 4.2 mmol/L, calcium 2.8 mmol/L, phosphate 5.3 mg/dL, Hb 10.7 g/dl, MCV 85.2 fL, WBC 9.61 k/uL, platelet 197 k/uL, albumin 3.1 g/dl, total protein 7.6 g/dl, Å秿§¿³J¥Õ§e²{3+, ÀY°©X¥ú§e²{
punched-out¯f¨_.°©Åè¤Á¤ùÀˬd§e²{©úÅãplasma cell neoplasm.Âå®vÃhºÃ¤ßŦ¤]¦³³Q¦¹¯e¯fªi¤Î.½Ð°Ý¤U¦C¤ßŦÀˬdµ²ªG,¦óªÌ»P³oÓÃhºÃ¸û¤£§k¦X?
|
A. | ¤ß¹q¹ÏA |
B. | ¤ß¹q¹ÏB |
C. | ¤ßŦ¶Wµªi§e²{¤ß¦ÙªÎ«p»Psparkling |
D. | ¤ßŦ¶Wµªi¥ª¤ß«Ç¥X²{restrictive filling pattern |
E. | ¤ßŦ¶Wµªi§e²{¤¤¦Ü««×¤T¦y佤³¬Âꤣ¥þ |
|
(A) | 20. |
¦³Ãö·s«¬¤fªA§Ü¾®¦å¾¯ªº´yz,¤U¦C¦óªÌ¿ù»~?
|
A. | apixaban¬O§@¥Î¦bthrombin |
B. | rivaroxaban¬O§@¥Î¦bfactor Xa |
C. | dabigatran 80%¥ÑµÇŦ¥NÁ |
D. | edoxaban half life¬O 9~11 ¤p®É |
E. | µLªkÂÇ¥Ñ prothrombin time¨ÓºÊ±±¸ÓÃĪ«§Ü¾®¦å®ÄªG |
|
(B) | 21. |
¤@¦ì65·³¤k©ÊÆb°©°©§é¶}¤M«á7¤Ñ,¥D¶D©I§lµ~¢;¶}¤M«e¦åÀ£¬°130/80²@¦Ì¨E¬W,©I§lµ~¢®É´ú¶q¤§¦åÀ£¬°80/50²@¦Ì¨E¬W.¦å®ñ¿@«×¥Ñ98%°¦Ü70%.¤ß¹q¹Ï¦p¹Ï.ȯZÂå®v¨S©â¦å´úD- dimer «Kª½±µ¦w±Æ¼v¹³Àˬd;¯Ý³¡¹q¸£Â_¼h±½´y¦pªþ¹Ï.½Ð°Ý¤U¦C´yz¦óªÌ¬°»~?
|
A. | ¸Ó¯f±w«Ü¦³¥i¯à¦]¶}¤M«áª×§É¦Ó¾ÉP²`³¡ÀR¯ß®ê¶ë |
B. | ¸ÓȯZÂå®vÀ³¸Ó©â¦åµ¥D- dimer¼ÆÈÀË´ú¥X¨Ó«á,¦A¶i¦æ¦w±Æ¼v¹³Àˬd |
C. | ¸Ó¯f±w¤§¦åÀ£°§Cªºì¦]¤§¤@¬O¥Ñ©ó¥k¤ß¦å²GµLªk¦^¨ì¥ª¤ß,¨Ó´£¨Ñ¨¬°÷¤ß¿é¥X¶q©ÒP |
D. | ¦¹®É©â¦å,¦å¤¤¨Å»Ä·|¤É°ª |
E. | D-dimer¹ï¦¹ªÍ³¡¦åºÞÅܤƪº¶EÂ_±Ó·P«×(sensitivity)>95% |
|
(B) | 22. |
¤@¦ì75·³¨k©Ê,¹L¥h¿©±w¿}§¿¯f,¦ý¦å¿}±±¨î¤£¨Î.©âµÒ¦³40¦~.¦åÀ£°ª¦ýªø¦~¥¼ªvÀø.³Ìªñ3Ó¤ë¥X²{¶¡·²©Ê¶_¦æ,Âå®vÃhºÃ¥L¦³¶gÃä°Ê¯ßªý¶ë©Ê¯e¯f (peripheral arterial occlusive disease),¦]¦¹¶}¥ß¸}½ï»PªÐ°Ê¯ß¦åÀ£¤ñÈ(ankle brachial index, ABI)Àˬd,½Ð°Ý¤U¦C´yz¦óªÌ¿ù»~?
|
A. | ABI ¥¿±`Ȧb1.0~1.4 |
B. | ABI<1.0 ¥i¥H½T¥ß¶EÂ_¶gÃä°Ê¯ßªý¶ë©Ê¯e¯f |
C. | ¹B°Ê«á¥ß§Y´ú¶qABI,¦pªGABI ¼ÆÈ©úÅã¤U°,¥i¥H¨ó§U¯gª¬¼Ò¸W¨â¥iªº¯f¤H¶EÂ_¶gÃä°Ê¯ßªý¶ë©Ê¯e¯f |
D. | °£«D¯f¤H¦³³W¹º¶i¦æ¦åºÞ««ØªvÀø (revascularization), ºÏ®¶¦åºÞ³y¼v( Magnetic Resonance Angiography) ¤£n³Q·í¦¨±`³W¿zÀˤu¨ã. |
E. | ABI¹ï¿©±w¶gÃä°Ê¯ßªý¶ë©Ê¯e¯f¤§¯f¤H,°£¤F¶EÂ_ªº¥\¥Î;ÁÙ¥i¥H¨ó§U§ä¥X¥i¯àµo¥Í«aª¬°Ê¯ßµ°¼Ëµw¤Æ¯e¯f(atherothrombotic event)·ÀIªº¤H |
|